FRIDAY, Sept. 27, 2024 (HealthDay News) — An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who’ve failed other medications, a new trial shows. The treatment, tulisokibart, spurred remission of symptoms in more than a quarter of patients, compared to only 1.5% of thoseContinue Reading